Insider buying last 90 days
No open-market insider purchases were filed for OMER in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every OMER insider filing, plotted on the chart in Gekko.Open OMER in Gekko
NASDAQ: OMER
Omeros (OMER) Stock Analysis & Forecast
Oct 12 close
$19.63−0.20 (−1.0%)
Gekko Brief
AI summaryOct 12 closeOmeros this week drew attention after Cantor Fitzgerald upgraded the stock from Neutral to Overweight, setting a $22.00 price target, citing positive physician feedback for Yartemlea, the company's stem-cell transplant treatment, and projected market share gains. Separately, shares fell 2.06% on 6 October to $18.51 despite strong second-quarter revenue of $28.53 million and adjusted EPS of $0.02, with commentary noting Yartemlea gaining traction even as near-term sentiment showed some weakness against stronger mid- and long-term signals.
Omeros closed at $19.63, down 1% on the day, with price sitting above both the 50-day ($17.87) and 200-day ($13.30) moving averages, and the 50-day above the 200-day. The GekkoIndex reads 54.2, placing the stock in the Neutral zone, down 3.1 over the past five readings. Price stands 9.2% below the Gekko Fair Value of $21.63.
Earnings are set for 12 November 2026, 30 days out and beyond a typical 20-trading-day holding window; the prior report on 13 August showed EPS of $0.02 against a $0.27 estimate, with a 25.4% reaction, part of a pattern of 7 beats in the last 8 quarters and an average absolute reaction of 19.5%. No insider, Congress or unusual options activity appears in the respective 90-day and 30-day windows, though one trailblazer holder is noted. Seasonally, the next 20 trading days have averaged +5.7% over 5 years, rising in 3 of them. Analyst consensus across 3 firms stands at a $27.50 target, with 2 buy ratings and 1 hold.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Omeros price vs fair value
Close $19.63200-day averageGekko Fair Value $21.63
Omeros quick facts
- Market cap
- $1.42B
- P/E ratio
- 15.7
- Forward P/E
- 87.7
- EPS, TTM
- $1.22
- Revenue, TTM
- $38.42M
- Profit margin
- 324.9%
- Dividend yield
- —
- Beta
- 2.57
- Volume
- 1.07M avg 1.37M
- 1-year return
- +330.5%
- Typical daily move
- ±3.6%
- Typical 20-day move
- ±18%
- 50-day average
- $17.87
- 200-day average
- $13.30
- Next earnings
- Nov 12
- Shares outstanding
- 72.39M
Omeros swing-trade checklist
Omeros scores 4 supportive, 1 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive1 mixed0 headwinds
- Trendsupportive
Above 50 and 200-day
Close $19.63 is above the 50-day ($17.87) and 200-day ($13.30) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
54.2, Neutral
Reading 54.2 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
9.2% below
Price is 9.2% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 31 days
Next report Nov 12, 2026, 31 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+5.7% on average
From this point in the calendar, the next 20 trading days averaged +5.7% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Omeros stock chart and price history
Omeros closed at $19.63 on Oct 12, 2026, +330.5% over the past year, inside a 52-week range of $4.06 to $21.24.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +7.4%
- 3 months
- +87.0%
- 6 months
- +72.5%
- 1 year
- +330.5%
The full OMER chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open OMER in Gekko
Follow Omeros through every session
Put OMER on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track OMER in GekkoFree for 7 days. No credit card required.
About Omeros
Omeros is a biopharmaceutical company that researches, develops, and brings to market medicines built from both small molecules and proteins, including therapies aimed at rare diseases. Its work centers on inflammation, conditions driven by the complement system, cancers tied to immune irregularities, and disorders involving addiction or compulsive behavior. The company is particularly known for narsoplimab, also called OMS721 or MASP-2, which has completed late-stage trials for a blood-clotting complication linked to stem-cell transplants and is being tested further for kidney disease, a rare blood disorder, and COVID-19.
Beyond its lead candidate, Omeros runs a broader pipeline spanning early and mid-stage trials, including treatments for opioid and nicotine dependence, compulsive and movement disorders, and a rare blood condition tied to the complement system. Its preclinical work extends to additional MASP-2 and MASP-3 inhibitors, antibody therapies, CAR T-cell and adoptive T-cell approaches for cancer, and research into receptor targets relevant to immune, metabolic, neurological, cardiovascular, and musculoskeletal diseases.
Founded in 1994 and based in Seattle, Washington, Omeros has its shares listed on the NASDAQ under the ticker OMER.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- omeros.com
Omeros GekkoIndex: the smart money zone
Omeros’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 54.2, in the Neutral zone, down 3.1 points over five sessions.
54.2Neutral
Down 3.1 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 33 | −0.6% | +0.1% | ||
| Accumulation | 206 | +3.0% | +5.0% | ||
| Neutral (current zone) | 396 | +2.2% | +14.7% | ||
| Distribution | 39 | +6.7% | −3.9% | ||
| Selling | 8 | Too few readings yet | |||
Average OMER share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the OMER price, zone by zone.Track OMER in Gekko
Is Omeros stock overvalued? Gekko Fair Value
Omeros trades 9.2% below Gekko Fair Value of $21.63, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Omeros shares are worth, recalculated every trading day.
$21.63
Gekko Fair Value, Oct 10, 2026
9.2% Undervalued
At the end of Aug 2026 the price was 27.6% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open OMER in Gekko
Omeros insider and Congress trading
No open-market insider purchases were filed for Omeros, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in OMER were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for OMER, plotted on the chart in Gekko.Open OMER in Gekko
Buybacks
Omeros has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $1.62M
- As a share of market cap
- 0.11%
From company filings.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds OMER.
1added0opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Omeros earnings: next date and track record
Omeros reports on Nov 12, 2026 (31 days away), and beat the EPS estimate in 7 of its last 8 reports.
Next earnings report
Nov 12, 2026
31 days away
- EPS estimate
- $0.03
- Revenue estimate
- $37.28M
7 of 8reports beat the EPS estimate
±19.5%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 13, 2026 AI summary
- What they said
- Omeros held its quarterly earnings call focused on commercial execution of Yartemlia (narsoplimab) for TA‑TMA, financial results, and capital structure actions. Management highlighted second-quarter net income of $13.2 million ($0.18/share) versus $56.1 million in Q1 driven largely by non‑cash mark‑to‑market fluctuations on the 2029 convertible notes; on a non‑GAAP basis (excluding embedded derivative remeasurements) adjusted net income was $1.8 million ($0.02/share) compared with a non‑GAAP adjusted net loss in Q1. Company generated $4.1 million net cash from operations in Q2, held $132 million cash and investments as of June 30, 2026, repurchased ~489k shares in the quarter and repurchased $30.5 million aggregate principal of 2029 convertible notes in June/July reducing outstanding 2029 notes by ~43%. Commercially, Yartemlia demonstrated strong first‑full‑quarter momentum with broad adoption across pediatric and adult centers, approximately 75% of orders from adults, consistent distributor inventory (~1.5 weeks), and favorable CMS NTAP reimbursement (up to ~$287k per course effective Oct 1). Management reiterated their expectation to be company‑wide cash flow positive by mid‑2027 and emphasized continued focus on driving adoption, expanding MASP‑2 franchise opportunities, and advancing the pipeline.
- Guidance
- Management reiterated prior guidance that the company expects to be cash flow positive company‑wide by mid‑2027. They declined to provide or update internal sales forecasts or other forward‑looking numeric guidance.
- Risks flagged
- Management prefaced remarks with standard forward‑looking statement caution pointing to the Form 10‑Q and 10‑K risk factor disclosures. Call referenced volatility from non‑cash mark‑to‑market remeasurements on convertible notes and small remeasurement losses related to note repurchases. Management also acknowledged potential month‑to‑month variability in sales and institutional inertia (diagnostic and adoption hurdles) that could slow uptake.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 13, 2026 | $0.02 est −$0.27 | $28.53M est $12.69M | +25.4% |
| May 13, 2026 | $0.57 est −$0.39 | $9.90M est $4.19M | −10.0% |
| Mar 31, 2026 | −$0.55 est −$0.52 | — est $1.60M | +23.1% |
| Nov 13, 2025 | −$0.19 est −$0.58 | — | +14.2% |
| Aug 14, 2025 | −$0.53 est −$0.55 | — est $313K | +3.3% |
| Mar 31, 2025 | −$0.55 est −$0.71 | $412K est $400K | −6.6% |
| Nov 13, 2024 | −$0.64 est −$0.77 | — | +63.1% |
| Aug 7, 2024 | −$0.97 est −$1.14 | — | −10.5% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Omeros stock forecast and analyst price targets
Analysts’ average 12-month price target for Omeros is $27.50, +40.1% from the last close, from 3 firms rating the stock in the last 90 days.
$27.50consensus 12-month target, +40.1% from the last close
Now $19.63Avg $27.50
Low $22High $33
Each firm’s latest rating in the last 90 days: 3 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 22 | Cantor Fitzgerald | $22 | +12.1% |
| Aug 13 | H.C. Wainwright | $33 | +68.1% |
| Aug 13 | Needham | — | — |
| Aug 3 | H.C. Wainwright | $33 | +68.1% |
| Jul 27 | Needham | — | — |
+14.7%average 20-day move after past Neutral readings
+5.7%average move over the next 20 trading days in the last 5 years
±3.6%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Omeros seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Omeros averaged +5.7% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +7.2% | 2 of 5 |
| Next 10 trading days | +2.7% | 2 of 5 |
| Next 15 trading days | +4.5% | 2 of 5 |
| Next 20 trading days | +5.7% | 3 of 5 |
| Next 30 trading days | +20.7% | 3 of 5 |
For scale, OMER’s typical 20-trading-day move in either direction is about 18%.
Omeros market cap and key statistics
Omeros’s market cap is $1.42B, with a P/E ratio of 15.7 and revenue of $38.42M over the last twelve months.
Valuation
- Market cap
- $1.42B
- P/E ratio
- 15.7
- Forward P/E
- 87.7
- EPS, TTM
- $1.22
- Gekko Fair Value
- $21.63
Trading
- Volume
- 1.07M
- Avg volume, 20 days
- 1.37M
- 52-week high
- $21.24
- 52-week low
- $4.06
- Shares outstanding
- 72.39M
Financials
- Revenue, TTM
- $38.42M
- Profit margin
- 324.9%
- Return on equity
- -576%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 2.57
- Typical daily move
- ±3.6%
- Typical 20-day move
- ±18%
Omeros stock news this week
Coverage of Omeros this week reads neutral: 1 positive, 2 neutral and 0 negative headlines.
- Cantor Fitzgerald upgraded Omeros to Overweight for Omeros stockAD HOC NEWS, Oct 8
- Avoiding Lag: Real-Time Signals in (OMER) MovementStock Traders Daily, Oct 7
- Omeros Corporation stock fell 2.06 percent as Yartemlea gains tractionAD HOC NEWS, Oct 7
Omeros peers
Omeros’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 14.7% above |
| JNJJohnson & Johnson | Neutral | 3.2% below |
| ABBVAbbVie | Distribution | 28.2% above |
| MRKMerck | Neutral | 8.0% below |
| AZNAstraZeneca | Accumulation | 41.7% below |
| PFEPfizer | Neutral | 8.0% below |
A peer links to its own page where one exists.
Omeros stock FAQ
What is Omeros’s market cap?
Omeros’s market cap is $1.42B at the Oct 12, 2026 close of $19.63, with 72.39M shares outstanding. The shares trade on a P/E ratio of 15.7.
What is the Omeros stock forecast?
The consensus analyst 12-month price target for Omeros is $27.50, +40.1% from the last close. Of the 3 firms that rated the stock in the last 90 days, 2 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Omeros stock overvalued or undervalued?
On Gekko’s estimate Omeros is undervalued: the Oct 12, 2026 close of $19.63 is 9.2% below Gekko Fair Value of $21.63. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Omeros report earnings next?
Omeros is expected to report on Nov 12, 2026 (31 days away). Analysts expect earnings of $0.03 per share on revenue of $37.28M. Omeros beat the earnings estimate in 7 of its last 8 reports, moving 19.5% on average across the report.
What is Omeros’s 52-week high and low?
Omeros’s 52-week high is $21.24 and its 52-week low is $4.06; it closed at $19.63 on Oct 12, 2026, +330.5% over the past year.
Is Omeros stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 5 items with data read as supportive (trend, fair value, earnings risk and seasonality), 1 as mixed (gekkoindex). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Omeros the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.